The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 17, 2025
Filed:
Apr. 25, 2022
Memorial Sloan-kettering Cancer Center, New York, NY (US);
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Sloan-kettering Institute for Cancer Research, New York, NY (US);
Memorial Hospital for Cancer and Allied Diseases, New York, NY (US);
Michel Sadelain, New York, NY (US);
Sascha P. Haubner, New York, NY (US);
Jorge Mansilla-Soto, Forest Hills, NY (US);
Xingyue He, Cambridge, MA (US);
Gary Shapiro, Cambridge, MA (US);
MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US);
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, New York, NY (US);
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, New York, NY (US);
MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA (US);
Abstract
The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.